Macitentan (OPSUMIT)
Endothelin receptor antagonist
Macitentan (OPSUMIT)
Forms and strengths
Form: TabletStrength: 10 mg film-coated tablet; 2.5 mg dispersible tablet
References
Indication
- Macitentan is used for the long-term treatment of pulmonary arterial hypertension (WHO Group I) to reduce disease-related complications in adults with WHO Functional Class II or III disease that is idiopathic, heritable, or associated with connective tissue disease or congenital heart disease.
- Macitentan is used for the same indication in pediatric patients aged 2 to less than 18 years.
- Macitentan is effective when used alone or in combination with a phosphodiesterase-5 inhibitor such as sildenafil.
Pregnancy
Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.
- Macitentan is contraindicated in women who are or may become pregnant, since pulmonary arterial hypertension itself carries a high mortality risk in pregnancy and macitentan was teratogenic in animal studies.
- In animal studies, macitentan caused cardiovascular and mandibular arch fusion abnormalities in rabbits and rats at all doses tested.
- Treatment should only be started in women of childbearing potential after a negative pregnancy test, with reliable contraception in place, and monthly pregnancy testing is recommended during treatment.
- Women should not become pregnant for at least 1 month after stopping macitentan.
Breastfeeding
- Macitentan is contraindicated in women who are breastfeeding.
- It is not known whether macitentan passes into human milk, though macitentan and its metabolites were found in the milk of lactating rats.
Geriatrics
- Dose adjustment is not required in patients 65 years of age and older.
- There is limited clinical experience in patients over 75 years of age, so macitentan should be used with caution in this group.
Pediatrics
- Macitentan is authorized for pediatric patients aged 2 to less than 18 years, using dispersible tablets dosed according to body weight.
- Safety and efficacy have not been established in children under 2 years of age, so use is not authorized in this age group.
- The safety profile in pediatric patients was generally consistent with adults, though upper respiratory tract infection, rhinitis, and gastroenteritis were reported more often than in the comparator group.
Dosage & Administration
- The recommended adult dose is one 10 mg film-coated tablet taken by mouth once daily.
- In pediatric patients weighing 10 kg to less than 20 kg, the dose is 5 mg daily, given as two 2.5 mg dispersible tablets.
- In pediatric patients weighing 20 kg to less than 40 kg, the dose is 7.5 mg daily, given as three 2.5 mg dispersible tablets.
- In pediatric patients weighing 40 kg or more, the dose is 10 mg daily, given as four 2.5 mg dispersible tablets.
- Dispersible tablets must be mixed into a small volume of room-temperature water, juice, or milk to form a suspension and given immediately, then followed with a little more liquid to ensure the full dose is taken.
- Film-coated tablets should be swallowed whole and can be taken with or without food.
- No dose adjustment is required for mild hepatic impairment, but macitentan is not recommended in patients with moderate or severe hepatic impairment due to lack of clinical experience.
- Macitentan is not recommended in patients undergoing dialysis; monitor blood pressure and hemoglobin in patients with moderate or severe renal impairment given an increased risk of hypotension and anemia.
- If a dose is missed, take it as soon as remembered, but skip it and resume the normal schedule the next day if it is nearly time for the next dose; never take two doses on the same day to make up for a missed one.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no clinical experience with macitentan overdose.
- In a study using single doses up to 600 mg, healthy subjects experienced headache, nausea, and vomiting.
- Overdose should be managed with standard supportive measures as needed.
- Because macitentan is highly bound to blood proteins, dialysis is not expected to be effective at removing it.
Common side effects
- Nasal and throat inflammation (nasopharyngitis) may occur.
- Headache may occur.
- Reduced red blood cell count (anemia) may occur.
- Bronchitis may occur.
- Urinary tract infection may occur.
- Increased or irregular uterine (menstrual) bleeding may occur.
- Sore throat (pharyngitis) may occur.
- Flu-like illness (influenza) may occur.
- Fluid retention or swelling (edema) may occur.
- Low blood pressure (hypotension) may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Decreased hemoglobin and anemia requiring transfusion have been reported; treatment is not recommended in patients with severe anemia.
- Elevated liver enzymes and liver injury, including cases with alternative causes such as autoimmune hepatitis, have been reported; treatment should be discontinued for significant liver enzyme elevations or symptoms of liver injury such as jaundice.
- Pulmonary edema can occur in patients with underlying pulmonary veno-occlusive disease.
- Male infertility may occur, based on decreased sperm counts observed with endothelin receptor antagonists; it is not known whether this effect is reversible.
- Hypersensitivity reactions, including angioedema, itching, and rash, have been reported.
- Pathologic changes in testicular tissue have been observed in animal studies at high exposures.
- Seek prompt medical attention for yellowing of the skin or eyes, unusual fatigue, swelling, fainting, or heavy vaginal bleeding.
Use with caution
- Use with caution, with hemoglobin measured before starting treatment, after one month, and periodically thereafter, given the known risk of anemia.
- Use with caution, with liver enzyme tests obtained before starting treatment and monthly during the first year, given the risk of liver injury.
- Do not start treatment in patients with liver aminotransferases already more than 3 times the upper limit of normal.
- Use with caution in patients with moderate or severe renal impairment, monitoring blood pressure and hemoglobin due to an increased risk of hypotension and anemia.
- Use with caution in men of reproductive potential, and counsel them about the possible effect on fertility.
- Use with caution in patients over 75 years of age, given limited clinical experience in this group.
- Consider pulmonary veno-occlusive disease if signs of pulmonary edema develop after starting treatment.
- Re-initiation of macitentan after stopping for liver enzyme elevations may be considered once levels return to normal in patients without symptoms of liver injury.
Contraindications
- Contraindicated in patients with known hypersensitivity to macitentan or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
- Contraindicated in women who are or may become pregnant.
- Contraindicated in women who are breastfeeding.
Drug interactions
- Macitentan is metabolized mainly by CYP3A4, with minor contributions from CYP2C8, CYP2C9, and CYP2C19.
- Strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, voriconazole, clarithromycin, and ritonavir, increase macitentan exposure, so caution is advised when these are combined with macitentan.
- Moderate dual inhibitors of CYP3A4 and CYP2C9, such as fluconazole and amiodarone, or the combination of a moderate CYP3A4 inhibitor (such as diltiazem, erythromycin, or cyclosporine) with a CYP2C9 inhibitor, can significantly increase macitentan exposure and require caution.
- Strong CYP3A4 inducers, such as rifampicin, substantially reduce macitentan exposure and should be avoided in combination, as this may reduce efficacy.
- Macitentan did not have a clinically relevant effect on the pharmacokinetics of sildenafil, and the combination has been shown to be effective and safe in pulmonary arterial hypertension.
- Macitentan did not affect the pharmacokinetics or effectiveness of hormonal contraceptives, so no dose adjustment is warranted.
- Macitentan did not have a clinically relevant effect on warfarin pharmacokinetics or its anticoagulant effect on INR.
- Macitentan did not affect the pharmacokinetics of rosuvastatin, a breast cancer resistance protein substrate, or of riociguat.
Food interactions
- Macitentan exposure is unchanged by food, so it can be taken with or without meals.
Time of administration
- Take macitentan once daily at about the same time each day, with or without food.
Storage
- Store at room temperature between 15°C and 30°C in the original package.
Patient take-away
- Macitentan (OPSUMIT) is a once-daily tablet used long-term to treat pulmonary arterial hypertension and reduce disease-related complications.
- Blood tests to check hemoglobin and liver function are needed before starting treatment and periodically during treatment.
- Macitentan must not be used during pregnancy or breastfeeding, and women of childbearing potential need a negative pregnancy test and reliable contraception before and during treatment.
- Seek prompt medical attention for yellowing of the skin or eyes, unusual tiredness, fainting, or heavy vaginal bleeding while on this medication.